Patient Profile: A 57-Year-Old Woman with NSCLC

Opinion
Video

Jyoti Patel, MD, presents the case of a patient with EGFR-mutated non–small cell lung cancer requiring treatment following osimertinib.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions and subtitles off, selected
      Recent Videos
      Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
      Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC
      2 experts in this video
      Looking Ahead and Key Takeaways in EGFRm NSCLC
      2 experts in this video
      Assessing the Adverse Effect Profile of Ami-Laz in Comparison With Other Combination Therapies in EGFRm NSCLC
      2 experts in this video
      COCOON: Discussion of Clinical End Points and Dose Modifications
      2 experts in this video
      COCOON Baseline Characteristics
      2 experts in this video
      Analysis of MARIPOSA & SKIPPirr Trials: Safety and Quality of Life
      2 experts in this video
      Insights from MARIPOSA: Impressions of the Intracranial Data
      2 experts in this video
      Overview of Study Design of the COCOON Trial
      2 experts in this video
      Clinical Insights: Experiences With Amivantamab-Lazertinib in EGFR-Mutant NSCLC
      2 experts in this video
      Decision-Making Factors in Choosing Combination Therapies in EGFR-Mutated NSCLC
      Related Content
      Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

      Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

      Tim Cortese
      April 23rd 2025
      Article

      The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.

      The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

      Improving NSCLC Surgery Recovery After Climate Disaster Exposure

      Leticia Nogueira, PhD, MPH
      March 31st 2025
      Podcast

      The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

      Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

      Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

      Tim Cortese
      April 20th 2025
      Article

      A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      Navigating Management and Dosing Considerations for Amivantamab in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      February 10th 2025
      Podcast

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      Phase 3 CROWN trial findings suggest that patients with ALK-positive NSCLC may maintain efficacy even after reducing lorlatinib dosing to mitigate AEs.

      Elucidating Lorlatinib Benefit, ALK TKI Sequencing in ALK-Positive NSCLC

      Roman Fabbricatore
      April 14th 2025
      Article

      Phase 3 CROWN trial findings suggest that patients with ALK-positive NSCLC may maintain efficacy even after reducing lorlatinib dosing to mitigate AEs.

      Disease-free survival and minimal residual disease event-free status was maintained for most patients with adjuvant osimertinib for EGFR-mutant NSCLC.

      Plasma-Based MRD Analysis May Predict Recurrence in EGFR-Mutant NSCLC

      Roman Fabbricatore
      April 12th 2025
      Article

      A disease-free survival and minimal residual disease event-free status was maintained for most patients with adjuvant osimertinib for EGFR-mutant NSCLC.